Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ...

This article first appeared on GuruFocus.

Release Date: November 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Aytu BioPharma Inc (NASDAQ:AYTU) reported net revenue of $13.9 million for the quarter, exceeding expectations, driven by strong performance in their ADHD portfolio. The ADHD portfolio saw a 10% increase in net revenue compared to the previous year, excluding a one-time rebate benefit. The launch of the new product, Xua, is on track for the end of calendar 2025, with significant advancements in preparations, including Salesforce training and product positioning. AYTU successfully extended the Exua method of use patent to September 2030, potentially expanding exclusivity beyond this date. The company has a strong cash position with $32.6 million in cash and cash equivalents as of September 30, 2025, and has reduced interest expenses significantly.

Negative Points

Net revenue for the quarter decreased from $16.6 million in the prior year, primarily due to a one-time rebate benefit in the previous year. The pediatric portfolio revenue decreased to $0.7 million from $1.3 million last year, attributed to manufacturing delays and a de-emphasis in marketing. Gross margin decreased to 66% from 72% in the previous year, although it improved on an equivalent basis excluding the rebate. Operating expenses, excluding certain costs, were $10.2 million, reflecting increased investments in the Exua launch. The company reported a negative adjusted EBITDA of $0.6 million for the quarter, compared to a positive $1.9 million in the previous year, due to Exua launch investments.

Q & A Highlights

Warning! GuruFocus has detected 5 Warning Signs with AYTU. Is AYTU fairly valued? Test your thesis with our free DCF calculator.

Q: How many territories were affected by the realignment, and what are your plans for the incentive compensation plan post-Exua launch? A: Approximately a third of the territories have been altered or reshaped, with some areas seeing denser coverage due to expected better coverage for Exua. The incentive compensation plan will heavily incentivize around Exua, focusing on activating new psychiatrists and rewarding deeper engagement with prescribers. (Josh Disbro, CEO)

Q: What are your pre-launch activities regarding payer engagement, and what are your expectations for coverage beyond Medicare? A: We are taking a wait-and-see approach with commercial payers to avoid jeopardizing best prices. We expect open access with Medicaid plans due to the mandate to cover antidepressants. We anticipate better coverage for Exua than our ADHD meds, with higher price points due to coverage on both commercial and government sides. (Josh Disbro, CEO)

Story Continues

Q: How much of your target prescriber market have you reached out to, and what feedback have you received? A: Feedback has been nearly universally positive, especially from psychiatrists already familiar with our products and RX Connect. We are focusing on areas where we know we can be successful, targeting physicians who are already prescribing our ADHD products. (Josh Disbro, CEO)

Q: Have you identified a target patient profile for Exua based on feedback from physicians? A: Yes, the target profile includes younger patients, aged 18 to 50, who are dissatisfied with current medications due to side effects like sexual dysfunction and weight gain. We aim to position Exua as an alternative before patients switch to other therapies. (Josh Disbro, CEO)

Q: How flexible is your supply chain to ramp up if demand exceeds expectations, and what are the margin expansion opportunities? A: We have flexibility with our contract manufacturer and enough supply to meet outsized forecasts. The cost of the product is about 2% of net revenue, and the royalty will drop from 28% to 24% once we hit $1.3 billion in aggregate sales. (Josh Disbro, CEO and Ryan Selhorn, CFO)

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments